Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 76 of 851 for:    Pancreatic Cancer AND Metastatic Pancreatic Cancer

BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03627390
Recruitment Status : Completed
First Posted : August 13, 2018
Last Update Posted : November 15, 2018
Sponsor:
Collaborators:
Meddoc
Norwegian University of Life Sciences
Information provided by (Responsible Party):
Meabco A/S

Brief Summary:
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.

Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Cancer Unresectable Pancreatic Cancer Drug: BP-C1 Drug: BP-C2 Phase 2

Detailed Description:

BP-C1, solution for injections 0.05%, is currently being developed for treatment of patients with metastatic breast cancer and metastatic pancreatic cancer with palliative intent. Active substance of the product, which is a novel platinum-containing anticancer agent developed for intramuscular administration, is a complex between cis-diammineplatinum(II) derived core and an amphiphilic polymer, containing a composition of benzene polycarboxylic acids. The amphiphilic characteristics of the polymer have resulted in a product with clear and significantly altered and improved properties compared to other platinum analogues, e.g. cisplatin, carboplatin and oxaliplatin.

BP-C1 preserves antitumour activity of its predecessors (e.g. cisplatin and carboplatin), additionally offering the following advantages that ensure favourable outcome of treatment in metastatic cancer patients:

  • injectable solution (intramuscular) does not cause injection site reactions;
  • can be administered at home by a nurse or a patient;
  • has an improved pharmacokinetic profile;
  • exerts an additional immunomodulatory activity.

BP-C2 is a novel lignin-derived polyphenolic composition with ammonium molybdate. BP-C2, given orally, is believed to reduce the toxicity of chemotherapeutic agents.

This is a single center, two arm, open label pilot study (phase IIa). The eligible patients will be allocated either to BP-C1 arm or to BP-C1+BP-C2 arm and treated for 32 days with further follow-up for 28 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open label, single center, two arm
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of BP-C1 in Treatment of Inoperable Pancreatic Cancer Patients: A Single Centre Pilot Study
Actual Study Start Date : December 19, 2014
Actual Primary Completion Date : March 4, 2016
Actual Study Completion Date : March 4, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Molybdenum

Arm Intervention/treatment
Experimental: BP-C1
Patients will be treated with BP-C1 for 32 consecutive days
Drug: BP-C1
BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Other Names:
  • Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
  • Benzene polycarboxylic acids complex with cis-diammineplatinum(II)

Experimental: BP-C1+BP-C2
Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
Drug: BP-C1
BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Other Names:
  • Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
  • Benzene polycarboxylic acids complex with cis-diammineplatinum(II)

Drug: BP-C2
BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
Other Name: molybdenum salts of benzene-polycarboxylic acids




Primary Outcome Measures :
  1. Change (%) in the sum of diameters of target lesions [ Time Frame: baseline to Day 32 of treatment ]
    Diameter of target lesions will be measured by computer tomography (CT) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

  2. Maximum Common Toxicity Criteria (CTC) score [ Time Frame: baseline to Day 32 of treatment ]
    Maximum CTC score will be recorded using NCI Common Toxicity Criteria v2.0 divided in 15 categories

  3. Sum CTC score [ Time Frame: baseline to Day 32 of treatment ]
    The Sum CTC score will be a sum of all registered CTC scores by 15 categories


Secondary Outcome Measures :
  1. Treatment response [ Time Frame: baseline to Day 32 of treatment ]

    In accordance with RECIST v1.1 the treatment response will be classified as 'complete response', 'partial response', 'stable disease' or 'progressive disease':

    Complete response (CR): disappearance of all target lesions. Partial response (PR): at least 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum of diameters.

    Progressive disease (PD): at least 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum might also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions will also be considered progression.

    Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.


  2. Scores of the general quality of life cancer questionnaire (EORTC QLQ-C30) [ Time Frame: baseline to Day 16 and Day 32 of treatment ]
    The EORTC QLQ-C30 is a general quality of life questionnaire for cancer patients. The questionnaire contains 30 questions. Three variables will be obtained from the EORTC QLQ-C30: the sum of scores C1 to C5 denoted as "Physical activity problem last week", the sum of scores C6 to C28 denoted as "Discomfort last week", and the sum of scores C29 and C30 denoted as "Health and quality of life"

  3. Number of registered adverse events [ Time Frame: screening to Day 32 of treatment and Day 28 of follow-up ]
    Adverse events (AEs) will be coded according to the MedDRA (version 16.1E). AEs will be systemized by system organ class and by preferred term. AEs will be analyzed by severity, seriousness and relatedness to the drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of all genders between 18 and 80 years of age with metastatic pancreatic cancer (unresectable pancreatic cancer with increased levels of cancer antigen 19-9), who had an expected survival time of at least 3 months.

Exclusion Criteria:

Patients fulfilling at least one of the following criteria will be excluded from participation in the study:

  • Abnormal liver function classified as total bilirubin >136 μmol/L (8.0 mg/dL)
  • Abnormal kidney function defined by serum creatinine >120 μmol/L (1.5 mg/dL).
  • Abnormal coagulation capacity defined by the relative arbitrary concentration of coagulation factors 2,7,10 < 0.7 or international normalized ratio >1.5.
  • Verified metastases to the brain.
  • Synchronous cancer except for non-melanoma skin cancer and early stage of cervical cancer.
  • Abnormal haematology status defined by hemoglobin < 6.0 g/dL, platelet count < 100,000/mm^3 or leucocytes < 3 x 10^9/L.
  • Clinically significant abnormal ECG.
  • Karnofsky performance status score <60%.
  • Pregnancy or breast-feeding.
  • Women of fertile age who do not want to be tested for possible pregnancy.
  • Uncontrolled bacterial, viral, fungal or parasite infection.
  • Under systemic treatment with corticosteroids or other immunosuppressive drugs in the last 21 days before start of the trial treatment.
  • Participating in another clinical trial with pharmaceuticals in the last six weeks before start of this trial treatment.
  • Not able to understand information.
  • Not willing or not able to give written consent to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03627390


Locations
Layout table for location information
Egypt
National Liver Institute, Menoufia University
Cairo, Egypt
Sponsors and Collaborators
Meabco A/S
Meddoc
Norwegian University of Life Sciences
Investigators
Layout table for investigator information
Principal Investigator: Tarek Ibrahim, MD Department of HPH Surgery, National Liver Institute, University of Menoufia, Egypt

Layout table for additonal information
Responsible Party: Meabco A/S
ClinicalTrials.gov Identifier: NCT03627390     History of Changes
Other Study ID Numbers: PaCa-BPC1/IIA
First Posted: August 13, 2018    Key Record Dates
Last Update Posted: November 15, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Meabco A/S:
Benzene polycarboxylic acids complex with cis-diammineplatinum(II)
BP-C1
Cis-coordinated complexes of platinum(II) with polymer of benzene polycarboxylic acids derived from lignin
Platinum analogue
Metronomic chemotherapy
Cisplatin
Pancreatic cancer
BP-C2
molybdenum salts of benzene-polycarboxylic acids
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases
Molybdenum
Trace Elements
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs